BioNTech SE (BNTX) posted a Q4 2025 adjusted net loss of €0.33 per share. Revenue was €907.4M. The German biotechnology company develops and commercializes immunotherapies to treat cancer and infectious diseases.
BioNTech’s portfolio includes multiple clinical-stage oncology candidates, with BNT111 in Phase 2 trials for advanced melanoma and BNT113 in Phase 2 for head and neck squamous cell carcinoma. The company also maintains programs in non-small cell lung cancer and various solid tumors across different trial phases.
A detailed analysis of BioNTech SE’s quarter follows shortly on AlphaStreet.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post BioNTech SE (BNTX) Reports Q4 Earnings first appeared on Alphastreet.
